Hetero
- All
- News
- Videos
-
Drug Firm Hetero Gets Approval To Produce, Sell Sputnik Light Vaccine
Drug firm Hetero on Monday said its biologics arm has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and sell Sputnik Light for restricted emergency use in India.
-
Positive Results In Phase 3 Trial Of Covid Pill, Says Hetero Pharma Group
Drug firm Hetero on Saturday announced positive results of Phase III trials of Movfor (Molnupiravir), an investigational oral antiviral COVID-19 medicine.
-
Rs 550-Crore "Unaccounted" Income Found During Tax Raids On Hetero Pharma Group: Report
The Income Tax Department detected "unaccounted" income of Rs 550 crore and seized over Rs 142 crore cash after it recently raided Hyderabad-based Hetero pharmaceutical group, official sources claimed on Saturday.
-
Hetero Gets Emergency Use Nod For Generic Version Of Covid Drug Tocilizumab
Indian drug developer Hetero said on Monday it has received emergency use approval from the country's health authorities to make a generic version of Roche Holding AG's COVID-19 drug.
-
Reduces Hospitalisation, Says Merck Of COVID-19 Drug, Seeks India's Ok
India's Hetero Labs said on Friday it sought emergency use nod from the local regulator for Merck's COVID-19 drug molnupiravir, after interim data from a late-stage trial showed it helped reduce hospitalisations and speed up recovery in mild cases.
-
Russia's Sputnik V Covid-19 Vaccine To Be Produced In India
RDIF and Hetero agree to produce over 100 million doses of the Sputnik V vaccine in India
-
India To Produce 100 Million Doses Of Sputnik Vaccine: Russia
One of the developers of Russia's Sputnik V coronavirus vaccine announced Friday that India-based drugmaker Hetero will produce over 100 million doses of the jab.
-
Hetero Labs Wins Approval To Sell COVID-19 Drug Favipiravir
The drug, priced at Rs 59 per tablet, is approved to treat mild to moderate COVID-19
-
Maharashtra, Delhi Among 5 States To Receive First Batch Of COVID-19 Drug
Hyderabad-based drugmaker Hetero, which has approval to manufacture and market the generic version of the experimental COVID-19 drug Remdesivir, has sent 20,000 vials to five states including Maharashtra and Delhi - the two worst affected states in the country.
-
Hyderabad-Based Hetero Prices Generic COVID-19 Drug At Rs 5,400 Per Vial
Hyderabad-based Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at Rs 5,400 ($71) per 100-milligram vial, the drug maker said on Wednesday, as it prepares to ship them to hospitals in the country.
-
Hyderabad-Based Hetero Gets Regulatory Nod To Make Gilead's COVID-19 Drug
Hetero said its generic version of US-based Gilead Science's Remdesivir will be marketed under brand name Covifor in India.
-
Indian Medicine Firm Pulls Heart Drug From US Amid Cancer Risk Probes
A unit of India's Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States, a notice on the U.S. regulator's website said, amid a wider probe into cancer risks associated with the drug.
-
Bengaluru-Based Puravankara Sells Land In Hyderabad For Rs 475 Crore
Puravankara Ltd has already launched housing projects on 20 acres of land parcel in Hyderabad and is also constructing commercial projects on over three acres of land.
-
Lupin, 5 Other Pharma Firms Ink Licensing Pact With Medicines Patent Pool
Indian pharma firms Aurobindo, Emcure, Hetero Labs, Laurus Labs, Lupin and Zydus Cadila are among the seven drug makers which have signed licensing pact with UN-backed Medicines Patent Pool (MPP) for producing HIV and hepatitis C drugs.
-
Hetero Launches Colorectal Cancer Drug In India
Drug firm Hetero on Monday launched a biosimilar of 'Bevacizumab', used in treating metastatic colorectal cancer (mCRC), under the brand name 'CizumabTM'.
-
Drug Firm Hetero Gets Approval To Produce, Sell Sputnik Light Vaccine
Drug firm Hetero on Monday said its biologics arm has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and sell Sputnik Light for restricted emergency use in India.
-
Positive Results In Phase 3 Trial Of Covid Pill, Says Hetero Pharma Group
Drug firm Hetero on Saturday announced positive results of Phase III trials of Movfor (Molnupiravir), an investigational oral antiviral COVID-19 medicine.
-
Rs 550-Crore "Unaccounted" Income Found During Tax Raids On Hetero Pharma Group: Report
The Income Tax Department detected "unaccounted" income of Rs 550 crore and seized over Rs 142 crore cash after it recently raided Hyderabad-based Hetero pharmaceutical group, official sources claimed on Saturday.
-
Hetero Gets Emergency Use Nod For Generic Version Of Covid Drug Tocilizumab
Indian drug developer Hetero said on Monday it has received emergency use approval from the country's health authorities to make a generic version of Roche Holding AG's COVID-19 drug.
-
Reduces Hospitalisation, Says Merck Of COVID-19 Drug, Seeks India's Ok
India's Hetero Labs said on Friday it sought emergency use nod from the local regulator for Merck's COVID-19 drug molnupiravir, after interim data from a late-stage trial showed it helped reduce hospitalisations and speed up recovery in mild cases.
-
Russia's Sputnik V Covid-19 Vaccine To Be Produced In India
RDIF and Hetero agree to produce over 100 million doses of the Sputnik V vaccine in India
-
India To Produce 100 Million Doses Of Sputnik Vaccine: Russia
One of the developers of Russia's Sputnik V coronavirus vaccine announced Friday that India-based drugmaker Hetero will produce over 100 million doses of the jab.
-
Hetero Labs Wins Approval To Sell COVID-19 Drug Favipiravir
The drug, priced at Rs 59 per tablet, is approved to treat mild to moderate COVID-19
-
Maharashtra, Delhi Among 5 States To Receive First Batch Of COVID-19 Drug
Hyderabad-based drugmaker Hetero, which has approval to manufacture and market the generic version of the experimental COVID-19 drug Remdesivir, has sent 20,000 vials to five states including Maharashtra and Delhi - the two worst affected states in the country.
-
Hyderabad-Based Hetero Prices Generic COVID-19 Drug At Rs 5,400 Per Vial
Hyderabad-based Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at Rs 5,400 ($71) per 100-milligram vial, the drug maker said on Wednesday, as it prepares to ship them to hospitals in the country.
-
Hyderabad-Based Hetero Gets Regulatory Nod To Make Gilead's COVID-19 Drug
Hetero said its generic version of US-based Gilead Science's Remdesivir will be marketed under brand name Covifor in India.
-
Indian Medicine Firm Pulls Heart Drug From US Amid Cancer Risk Probes
A unit of India's Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States, a notice on the U.S. regulator's website said, amid a wider probe into cancer risks associated with the drug.
-
Bengaluru-Based Puravankara Sells Land In Hyderabad For Rs 475 Crore
Puravankara Ltd has already launched housing projects on 20 acres of land parcel in Hyderabad and is also constructing commercial projects on over three acres of land.
-
Lupin, 5 Other Pharma Firms Ink Licensing Pact With Medicines Patent Pool
Indian pharma firms Aurobindo, Emcure, Hetero Labs, Laurus Labs, Lupin and Zydus Cadila are among the seven drug makers which have signed licensing pact with UN-backed Medicines Patent Pool (MPP) for producing HIV and hepatitis C drugs.
-
Hetero Launches Colorectal Cancer Drug In India
Drug firm Hetero on Monday launched a biosimilar of 'Bevacizumab', used in treating metastatic colorectal cancer (mCRC), under the brand name 'CizumabTM'.
